WallStSmart

Chemed Corp (CHE)vsFresenius Medical Care Corporation (FMS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Fresenius Medical Care Corporation generates 649% more annual revenue ($19.43B vs $2.60B). CHE leads profitability with a 10.6% profit margin vs 4.8%. FMS appears more attractively valued with a PEG of 0.73. CHE earns a higher WallStSmart Score of 63/100 (C+).

CHE

Buy

63

out of 100

Grade: C+

Growth: 7.3Profit: 7.5Value: 5.0Quality: 6.0
Piotroski: 3/9Altman Z: 5.69

FMS

Buy

58

out of 100

Grade: C

Growth: 4.7Profit: 5.0Value: 9.3Quality: 6.0
Piotroski: 6/9Altman Z: 1.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for CHE.

FMSUndervalued (+68.6%)

Margin of Safety

+68.6%

Fair Value

$76.58

Current Price

$22.35

$54.23 discount

UndervaluedFair: $76.58Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CHE3 strengths · Avg: 9.3/10
Return on EquityProfitability
30.6%10/10

Every $100 of equity generates 31 in profit

Altman Z-ScoreHealth
5.6910/10

Safe zone — low bankruptcy risk

EPS GrowthGrowth
43.7%8/10

Earnings expanding 43.7% YoY

FMS3 strengths · Avg: 9.3/10
P/E RatioValuation
11.7x10/10

Attractively priced relative to earnings

Price/BookValuation
0.8x10/10

Reasonable price relative to book value

PEG RatioValuation
0.738/10

Growing faster than its price suggests

Areas to Watch

CHE4 concerns · Avg: 3.8/10
PEG RatioValuation
1.904/10

Expensive relative to growth rate

P/E RatioValuation
26.1x4/10

Moderate valuation

Price/BookValuation
8.1x4/10

Trading at 8.1x book value

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

FMS4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
1.4%4/10

1.4% revenue growth

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Return on EquityProfitability
7.5%3/10

ROE of 7.5% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : CHE

The strongest argument for CHE centers on Return on Equity, Altman Z-Score, EPS Growth.

Bull Case : FMS

The strongest argument for FMS centers on P/E Ratio, Price/Book, PEG Ratio. PEG of 0.73 suggests the stock is reasonably priced for its growth.

Bear Case : CHE

The primary concerns for CHE are PEG Ratio, P/E Ratio, Price/Book.

Bear Case : FMS

The primary concerns for FMS are Revenue Growth, Altman Z-Score, Return on Equity. Thin 4.8% margins leave little buffer for downturns.

Key Dynamics to Monitor

FMS carries more volatility with a beta of 0.83 — expect wider price swings.

CHE is growing revenue faster at 8.8% — sustainability is the question.

FMS generates stronger free cash flow (620M), providing more financial flexibility.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

CHE scores higher overall (63/100 vs 58/100). FMS offers better value entry with a 68.6% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Chemed Corp

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Chemed Corporation provides hospice and hospice services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers across the United States. The company is headquartered in Cincinnati, Ohio.

Visit Website →

Fresenius Medical Care Corporation

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America and internationally. The company is headquartered in Bad Homburg, Germany.

Visit Website →

Want to dig deeper into these stocks?